(Q45857094)

17 December 2017

title

Safety and pharmacokinetics of a recombinant fusion protein linking coagulation factor VIIa with albumin in healthy volunteers (English)

1 reference

17 December 2017

1 reference

G Golor

1

1 reference

17 December 2017

D Bensen-Kennedy

2

1 reference

17 December 2017

S Haffner

3

1 reference

17 December 2017

R Easton

4

1 reference

17 December 2017

K Jung

5

1 reference

17 December 2017

T Moises

6

1 reference

17 December 2017

J-P Lawo

7

1 reference

17 December 2017

C Joch

8

1 reference

17 December 2017

A Veldman

9

1 reference

17 December 2017

publication date

1 November 2013

1 reference

17 December 2017

Journal of Thrombosis and Haemostasis

published in

1 reference

17 December 2017

volume

11

1 reference

17 December 2017

issue

11

1 reference

17 December 2017

page(s)

1977-1985

1 reference

17 December 2017

A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group

cites work

1 reference

Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients.

21 January 2018

1 reference

Pharmacokinetics and pharmacodynamics of recombinant factor VIIa

21 January 2018

1 reference

Safety and pharmacokinetics of a glycoPEGylated recombinant activated factor VII derivative: a randomized first human dose trial in healthy subjects

21 January 2018

1 reference

Evaluation of the safety and pharmacokinetics of a fast-acting recombinant FVIIa analogue, NN1731, in healthy male subjects

21 January 2018

1 reference

Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia

21 January 2018

1 reference

Exploratory study on the reversal of warfarin with rFVIIa in healthy subjects

21 January 2018

1 reference

Overview of the human pharmacokinetics of recombinant activated factor VII.

21 January 2018

1 reference

Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial

21 January 2018

1 reference

On-demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and maintaining predictable efficacy with recombinant activated factor VII.

21 January 2018

1 reference

Prophylaxis in 10 patients with severe haemophilia A and inhibitor: different approaches for different clinical situations

21 January 2018

1 reference

Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors

21 January 2018

1 reference

Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/JTH.12409

1 reference

17 December 2017

1 reference

17 December 2017